Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Cahill Financial Advisors Inc.

Cahill Financial Advisors Inc. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 8.6% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,571 shares of the medical instruments supplier’s stock after buying an additional 124 shares during the quarter. Cahill Financial Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $379,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp raised its holdings in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Finally, Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $45,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $224.00 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $235.15 and its 200 day moving average price is $234.55. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The firm has a market cap of $64.74 billion, a P/E ratio of 37.71, a PEG ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company posted $3.42 EPS. The business’s revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BDX shares. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.